January 26, 2022 | January Payne
Director of Public Relations
Monday, July 18, 2022
New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field
Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.
Wednesday, February 16, 2022
Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually.
Thursday, December 16, 2021
Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers
An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of Medicine. The University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol.
Tuesday, December 14, 2021
UM School of Medicine’s Office of Public Affairs and Communications Honored with 2021 PRSA ‘Best In Maryland’ Award
The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 “Best in Maryland Award,” the PRSA’s highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021.
Wednesday, September 08, 2021
UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates
In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia.
Wednesday, July 07, 2021
Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.
Wednesday, June 09, 2021
Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.
Tuesday, March 16, 2021
New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel
Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.
Thursday, January 21, 2021
On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.
Tuesday, January 05, 2021
Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.
Tuesday, January 05, 2021
University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate
Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.
Thursday, November 19, 2020
Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine
Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.
Friday, November 13, 2020
UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses
Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.
Tuesday, June 16, 2020
UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.
Tuesday, June 02, 2020
UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa
The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.
Monday, June 01, 2020
In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.
Thursday, May 28, 2020
UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.
Thursday, May 21, 2020
UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.
Tuesday, May 05, 2020
In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Thursday, April 23, 2020
Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Friday, April 10, 2020
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.
Wednesday, October 30, 2019
UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research
Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of Medicine (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.
Monday, October 21, 2019
UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine
Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.
Monday, August 19, 2019
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Wednesday, July 17, 2019
Vaccines Tested in UM School of Medicine’s Center for Vaccine Development Protect Children Around the World
For 30 years, the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) has collaborated with the Pediatric Center of Frederick to test vaccines used in pediatric care.
Friday, March 08, 2019
UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia
Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.
Wednesday, December 26, 2018
Multicenter Trial Supports Use of Topical Antibiotic as a Tool to Eliminate Staph Colonization in NICU Babies
A team of doctors led by Karen L. Kotloff, M.D., University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), has performed a clinical trial involving multiple hospitals that tested the effectiveness of applying a topical antibiotic known as mupirocin for prevention of Staphylococcus aureus (SA) infection in babies in the neonatal intensive care unit (NICU). This study was published in the journal Pediatrics.
Thursday, December 20, 2018
Data collected from the Global Enteric Multicenter Study (GEMS), a multi-site research project studying diarrheal diseases that was designed and coordinated by researchers in the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), are now available to scientists on two online data resources.
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Sunday, October 28, 2018
American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research
Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).
Friday, February 24, 2017
Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS). The research was conducted by scientists at the University of Maryland School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Sunday, November 15, 2015
University of Maryland School of Medicine Study Finds that Ebola Vaccine is Safe and Stimulates Strong Immune Responses in Adults in Mali and USA
A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published today in the journal Lancet Infectious Disease.
Friday, April 14, 2000
The COVID-19 pandemic has changed many aspects of our lives, from the way we shop and eat to how we connect with family and friends. While the virus itself has had strong and sometimes devastating effects on our community, the fear of its potential impact continues to influence responses and even cripple thoughts and actions.